Current guidelines do not systematically recommend 18F-FDG PET/CT for breast cancer staging; and the recommendations and level of evidence supporting its use in different groups of patients vary among guidelines. This review summarizes the evidence about the role of 18F-FDG PET/CT in breast cancer staging and the therapeutic and prognostic impact accumulated in the last decade. Other related aspects, such as the association of metabolic information with biology and prognosis are considered and evidence-based recommendations for the use of 18F-FDG PET/CT in breast cancer staging are offered. We systematically searched MEDLINE for articles reporting studies with at least 30 patients related to clinical questions following the Problem/Population, Intervention, Comparison, and Outcome framework. We critically reviewed the selected articles and elaborated evidence tables structuring the summarized information into methodology, results, and limitations. The level of evidence and the grades of recommendation for the use of 18F-FDG PET/CT in different contexts are summarized. Level III evidence supports the use of 18F-FDG PET/CT for initial staging in patients with recently diagnosed breast cancer; the diagnostic and therapeutic impact of the 18F-FDG PET/CT findings is sufficient for a weak recommendation in this population. In patients with locally advanced breast cancer, level II evidence supports the use of 18F-FDG PET/CT for initial staging; the diagnostic and therapeutic impact of the 18F-FDG PET/CT findings is sufficient for a strong recommendation in this population. In patients with recently diagnosed breast cancer, the metabolic information from baseline 18F-FDG PET/CT is associated with tumor biology and has prognostic implications, supported by level II evidence. In conclusion, 18F-FDG PET/CT is not recommended for staging all patients with early breast cancer, although evidence of improved regional and systemic staging supports its use in locally advanced breast cancer. Baseline tumor glycolytic activity is associated with tumor biology and prognosis.
Introduction
Among females worldwide, breast cancer (BC) is the most frequently diagnosed cancer, with a 5-year prevalence of 31.4% and is the leading cause of cancer death, accounting for 15.5% of all cancer deaths. 1, 2 The diagnosis of BC is based on clinical examination in combination with imaging and is confirmed by histopathological assessment. Imaging includes bilateral mammography and ultrasound of the breast and regional lymph nodes.
Accurate staging is important for management decisions and prognosis in patients with newly diagnosed BC. All patients with newly diagnosed BC undergo regional staging including axillary and internal mammary lymph node evaluation and those with a high risk of early distant metastases also undergo systemic staging including sites beyond the regional lymph nodes. Magnetic resonance imaging (MRI) of the breast and fluorine-18 fluorodeoxyglucose (18F-FDG) positron emission tomography/ computed tomography (PET/CT) are not routinely recommended for initial staging. [3] [4] [5] [6] [7] [8] Apart from imaging, in patients with clinically positive axilla, pre-treatment disease staging includes histopathological examination of the primary tumor and cytology/ histology of the axillary lymph node (ALN) specimens obtained using ultrasound-guided fine-needle aspiration biopsy or core biopsy to determine whether ALN dissection is needed. In patients with clinically negative axilla, the current standard of ALN staging in early-stage BC is sentinel lymph node biopsy. 5, 6 According to BC guidelines such as National Comprehensive Cancer Network (NCCN), European Society for Medical Oncology (ESMO), Spanish Society of Medical Oncology (SEOM), and the National Institute for Care Excellence (NICE), 18F-FDG PET/CT is not indicated in women with apparently early-stage (I or II) BC or even in those with operable stage III BC; [3] [4] [5] [6] [7] [8] it is considered optional for women with suspicious or equivocal findings on CT or MRI and for women with locally advanced BC, especially those with advanced axillary nodal disease, because the risk of early distant metastases is high enough to justify systemic staging as part of the initial evaluation. In this setting, 18F-FDG PET/CT can detect metastases that are not visible on other modalities, and these findings can change treatment options. However, the levels of evidence and the recommendations for the use of 18F-FDG PET/CT vary among guidelines, basically because different guidelines use different quality evaluation scales and most are designed for the assessment of treatment-related studies rather than for diagnosis. Table 1 summarizes the current guidelines recommendations and level of evidence for using 18F-FDG PET/CT in BC staging.
Given the evolving role of 18F-FDG PET/CT in the management of BC patients and the low level of evidence for its use in initial staging reported in the guidelines, we reviewed and summarized the current evidence to offer evidence-based recommendations for the use of PET/CT in this setting.
Materials and methods
The search strategy was structured following the PICO framework, in which was the reference standard. Alternatively, conventional imaging (CT, ultrasonography (US), and/or bone scintigraphy (BS)) was used. • • O stands for outcome: sensitivity, specificity, change in stage compared to staging done by conventional imaging, prognosis, and costs.
We searched MEDLINE to identify studies published in English between January 2006 and March 2016 that contained the above-mentioned PICO terms or synonymous terms in titles and/or abstracts. To select studies, one investigator reviewed the titles of all the studies identified in the search and excluded those not related with the main objective: initial PET (staging). Next, we reviewed the abstracts of the included titles and obtained the complete articles of those that reported systematic reviews or original studies using 18F-FDG PET, 18F-FDG PET/CT, or both techniques in a sample at least of 30 patients.
Two investigators examined all the papers that fulfilled these criteria and excluded duplicated studies and reviewed articles or meta-analyses that were superseded by more recent ones. Moreover, studies included in systematic reviews or meta-analyses were excluded when a systematic review or meta-analysis answered the question they explored.information into methodology, results, and limitations. We assessed the level of evidence for the use of 18F-FDG PET in each situation and established the recommendation grades following the NICE adaptation 9 of the levels of evidence for diagnostic studies of the Oxford Centre for Evidence-Based Medicine and the Centre for Reviews and Dissemination (Table 2) . Recommendations were simplified to consider grade A or B as a strong recommendation and grade C or D as weak recommendation.
Cost-effectiveness studies were evaluated using the Scottish Intercollegiate Guidelines Network (SIGN) 10 scale, which ranges from (++), when the study fulfilled all or most of the quality criteria, to (−), when it fulfilled few or none of the quality criteria.
In the assessment of each study, the gold standard considered valid was histological confirmation of lymph node or distant metastases.
We reviewed all the information from the literature searches to answer the following main question:
Question (a):
Is it necessary to introduce 18F-FDG PET/CT imaging in conventional staging in all cases or only in cases with certain clinical stages or molecular characteristics (risk stratification)?
Moreover, we considered other, secondary questions to answer the main question: 
Results
The levels of evidence and grades of recommendations for the answers to the questions were as follows: Tables 3-5.  2a. 18F-FDG PET/CT should be used in locally advanced BC for initial staging. Evidence level II, strong recommendation. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] For more information, see Tables 3-5.  3a. 18F-FDG PET/CT should be used in high-risk patients, such as those with inflammatory BC. Evidence Level II, strong recommendation. In triple-negative BC, there is limited evidence to recommend the systematic use of the technique. [29] [30] [31] [32] [33] [34] [35] For more detailed information, see Table 6 . 4a.
Patients' age at diagnosis is not in itself, independent of clinical stage or molecular biology, a sufficient criterion to indicate 18F-FDG PET/CT. 35 Evidence level IV, weak recommendation. 14, 20, [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] For more detailed information, see Table 7 . Question (d): Do 18F-FDG PET/CT findings result in a significant change in therapeutic management?
In patients with recently diagnosed BC, 18F-FDG PET/ CT results in a significant enough change in the therapeutic management to recommend it. Evidence level III, low recommendation. 14, 20, [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] For more detailed information, see Table 7 .
Question (e): Is glycolytic activity associated with tumor biology? In patients with recently diagnosed BC, the baseline glycolytic activity on 18F-FDG PET/CT is associated with tumor biology. Evidence level II [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] (Table 8) . Question (f): Does the metabolic information from a baseline 18F-FDG PET/CT have implications for the patient's prognosis? In patients with recently diagnosed BC, the metabolic information from a baseline 18F-FDG PET/CT has implications for the patient's prognosis. Evidence level II 28, 32, 33, 39, 47, [57] [58] [59] [60] [61] (Table 9) . Question (g): Is staging with 18F-FDG PET/CT cost-effective? There is not enough evidence to address the cost-effectiveness of 18F-FDG PET/CT 62, 63 (Table 10) .
Discussion

18F-FDG PET/CT in regional and distant staging
In the preoperative work-up of early-stage BC with clinically negative axilla, 18F-FDG PET/CT can be omitted because it hardly affects the initial staging and treatment planning in most patients. In regional staging, 18F-FDG PET/CT is less sensitive than sentinel lymph node biopsy in assessing ALN involvement. The low prevalence of distant metastases and the risk of false-positive findings retract from the usefulness of 18F-FDG PET/CT for distant staging in these patients. [11] [12] [13] By contrast, in patients with positive axilla, especially those with locally advanced BC, 18F-FDG PET/CT can be • • Inclusion criteria: T1 (early BC).
• • Objective: detection of lymph node involvement.
• • Evaluation criteria: moderately intense FDG uptake (higher than background) and for lesions near 1 cm, any uptake slightly higher than background. Blinded assessment.
• • Reference standard: histopathology.
• • Positive axillary nodes by PET/CT in 19 patients and positive node in periclavicular region in 2 patients (3%).
• • Se, Sp, PPV, and NPV of PET/CT were 73%, 100%, 100%, and 72%, respectively.
• • • Evaluation criteria: FDG uptake higher than background. Blinded assessment.
• • 34 (68%) had nodal involvement.
• • PSF reconstruction detected more involved nodes than OSEM reconstruction (p = 0.003).
• • The Se of PSF reconstruction was superior to OSEM reconstruction independent of lymph node size.
• • • Reference standard: 8 studies used ALND for all patients, 12 used a combination of ALND and SLNB, 3 did not specify (only stating "histology"), and 3 used other methods for some patients.
• • PET or PET/CT (26 studies, 2591 patients): Mean Se 63% (95% CI: 52%-74%; range 20%-100%) and mean Sp 94% (95% CI: 91%-96%; range 75%-100%).
• • PET/CT (7 studies, 862 patients). Mean Se 56% (95% CI: 44%-67%) and mean Sp 96% (95% CI: 90%-99%).
• • PET only (19 studies, 1729 patients). Mean Se 66% (95% CI: 50%-79%) and mean Sp 93% (95% CI: 89%-96%).
• • Micrometastasis: Mean Se 11% (95% CI: 5%-22%) for micrometastases (≤2 mm; 5 studies; 63 patients), and 57% (95% CI: 47%-66%) for macrometastases (>2 mm; 4 studies; 111 patients).
• • Ultrasmall super-paramagnetic iron oxide (USPIO)-enhanced MRI (5 studies, 93 patients). Mean Se 98% (95% CI: 61%-100%) and mean Sp 96% (95% CI: 72%-100%).
• • Gadolinium-enhanced MRI (3 studies, 187 patients). Mean Se 88% (95% CI:
78%-94%) and mean Sp 73% (95% CI: 63%-81%).
• • In vivo proton magnetic resonance spectroscopy (1 study, 27 patients). Se 65% (95% CI: 38%-86%) and Sp 100% (95% CI: 69%-100%).
• • None of the studies included directly compared PET with MRI.
• • Patients were not recruited prospectively and consecutively (3 studies);
unclear inclusion in 12.
• • • Inclusion criteria: T1 BC.
Comparison of PET/CT with US and cMRI for lymph node detection.
• • Evaluation criteria: higher level of FDG uptake than the background
Reference standard: histopathology.
• • In total, 26% of patients had ALNMs.
• • The Se, Sp, PPV, NPV, and Acc of US for determining ALNMs were 45%, 89%, 59%, 82%, and 77%, respectively.
• •
The Se, Sp, PPV, NPV, and Acc of PET/CT were 45%, 94%, 73%, 83%, and 81%, respectively.
The combination including cMRI and PET/CT was the most accurate with Se, Sp, PPV, NPV, and Acc of 39%, 99%, 92%, 82%, and 83%, respectively.
Retrospective.
• • • Evaluation criteria: both apparent and suspected FDG accumulations were considered to be positive.
• • In 15/24 (63%) patients, axillary nodal involvement was evident by pathological examination after ALND. Micrometastases were detected in two patients.
• • SLNB afforded the highest Se (93%) in terms of detection of axillary metastasis.
• • PET/CT detected ALNM in 11 patients (1 FP). PET/CT did not detect metastases in 5 patients with axillary involvement (2 had micrometastases and 3 had subcentrimetric metastases).
The sensitivity, NPV, and Acc of PET/CT were 67%, 62%, and 75%, respectively, thus higher than the equivalent values of either DCE-MRI or DWI.
• • Small population.
• • Non-blinded evaluation between the diagnostic tests.
III (continued)
References Methodology
Results
Limitations
Level of evidence Segaert et al. 20 
• •
Retrospective. 70 patients.
• • Inclusion criteria: IIB-III LABC.
• • Objective: comparison of PET/CT versus conventional staging for lymph node involvement.
• • Blinded assessment.
• • Evaluation criteria: a focally increased FDG activity above physiological mediastinal tracer uptake.
• • Reference standard: histopathology or clinical and imaging follow-up.
• • 14/70 patients had primary surgery with ALND (8 with involved lymph nodes). In 56 others, neoadjuvant or systemic therapy was administered prior to local therapy.
• • PET/CT: Se, Sp, and NPV for nodal status were 63%, 100%, and 67%, respectively.
• • Conventional staging : Se, Sp, and NPV for nodal involvement were 88%, 100%, and 86%, respectively.
• • Retrospective. Nonrepresentative population.
• •
Histopathological
confirmation not available in all cases.
III
Choi et al. 21 
• •
Retrospective. 154 patients.
• • Inclusion criteria: Early and LABC.
• • Objective: PET/CT versus US and MRI for lymph node involvement.
• • Evaluation criteria: foci with pathologic uptake higher than the liver activity.
• • Reference standard: Histopathology or additional images and follow-up.
• • PET/CT detected extra-axillary lymph node metastases in 8 patients and distant metastasis in 13.
• • Histological confirmation of ALNMs in 51 patients. PET/CT detected metastatic axillae with 37% Se and 96% Sp; US had 41% Se and 94% Sp and MRI had 40% Se and 88% Sp.
• • Retrospective. Nonrepresentative and heterogeneous population.
• • Non-blinded evaluation with CI.
• • • Inclusion criteria: stages: pTx-pT4 and pN0-pN3.
• • Objective: PET/CT versus US for lymph node involvement. Blinded assessment.
• • Evaluation criteria: focally increased PET signal.
• • Histopathology classified 54 axillary lymph nodes as negative and 37 as positive for ALNM.
• • PET/CT: Se, Sp, PPV, NPV, and Acc for the detection of ALNMs were 54%, 89%, 77%, 74%, and 75%, respectively.
• • US: Se, Sp, PPV, NPV, and Acc were of 38%, 78%, 54%, 65%, and 62%, respectively.
• • FDG PET/CT was significantly more accurate than ultrasound and detected extra-axillary locoregional lymph node metastases that had not been detected by another imaging modality in 7 (8%) patients. • • Few studies included.
• • 2/6 studies were retrospective.
• • There was no single clinical and imaging follow-up strategy, which may have affected the evaluation of whole-body PET/PET-CT.
• • Wide variation in patient population, imaging techniques, study design, and quality in the selected studies.
III
Segaert et al. 20 
• •
• • Inclusion criteria: LABC (IIB-III).
• • Objective: PET/CT versus CS (chest X-ray, abdominal US, and BS) for M1 detection.
• • Reference standard: clinical and imaging follow-up.
• • Global Se and Sp in the M1 diagnosis of CS: 70% and 98%, respectively.
• • Se was 86% for CS, 75% for PET, and 96% for PET/CT.
• • PET/CT did change stage IV and treatment in 10%.
• • Retrospective. Selection bias. • • Blinded assessment with reference standard.
• • Reference standard: histopathological confirmation or additional imaging techniques.
• • Distant metastases were found in 20 (49%) patients at staging, 7 (17%) of whom were not known to have metastases before undergoing PET/CT.
• and decreased the stage in 5.
• • In 7 of 9 cN0 patients, the axillary lymph node positivity on PET/CT was correct.
• • PET/CT diagnosed extra-axillary involvement in 33 patients and distant lesions in 18/59 (31%).
Comparison of whole-body PET and CT scans was not feasible.
• • • Concordance between PET/CT and DCE-CT was good for breast tumor localization, poor for skin infiltration, and fair for axillary node involvement.
• • 19 (38%) patients had metastases on PET/CT.
• 
• • Single-center design.
• • Selection biases. Unsuitable range of patients.
• • • Unsuspected extra-axillary regional nodes were found in 15/134 (11%) patients and distant metastases in 20/134 (15%), and both were found in 7/134 (5%).
• • • Blinded assessment.
• • Reference standard in stage IV: clinical and imaging follow-up.
• • Change in stage and therapy: 10% (stage IV).
• • Changes in nodal status are not reported.
• • Reference standard: histological data of IMN.
• • In 33 patients, PET/CT discovered distant metastases.
• • 62/216 patients had visible IMNs on FDG PET/CT, and histological confirmation was obtained in 31 patients: 27 metastatic and 4 non-metastatic nodes (PPV 87%).
• • PET/CT was performed after FNAB in 45% of patients.
• • • Inclusion criteria: BC with clinically negative axillary node.
• • Objective: diagnostic and therapeutic impact evaluation.
• • Reference standard: histopathology, additional images or follow-up.
• • Extra-axillary node metastasis was identified in 1% who had IMN.
• • There was no distant metastasis, but coexisting primary tumor was detected in 3%.
• • PET/CT changed treatment in 4%.
• • PET/CT hardly affected the initial staging or treatment plan of BC with clinically negative axillary node
• • • Reference standard: pathological assessment.
• • Tumors with negative ER were associated with higher SUVmax. Tumors with overexpression of HER2, tumor grade 3, axillary lymph node involvement, tumor histopathology, and increased tumor size were associated with higher SUVmax. However, PR status was not associated with SUVmax.
• • Retrospective study. Nonrepresentative population.
• • Non-blinded evaluation.
• • Lack of complete surgical removal of the tumor for estimating the total tumor volume.
III
García-Vicente et al. 51 • • Prospective multicenter study. 168 patients.
• • Inclusion criteria: LABC.
• • Dual time-point acquisition (whole-body + thoracic acquisition).
• • Objective: correlation of SUVmax (SUV-1 and SUV-2) and RI with molecular subtypes.
• • Reference standard: pathological assessment.
• • There were significant differences between SUV-1 and SUV-2 and the different subtypes, with higher SUV values in pure HER2 (+) and TN. No significant differences were found with respect to RI.
• • Primary tumor 18F-FDG uptake and tumor-tobackground SUVmax ratios were significantly associated with tumor size, histological type, histological grade, pleomorphism, mitosis count, lymphatic invasion, necrosis, estrogen negativity, high Ki-67 level, axillary lymph node involvement, and triple negativity.
• • Retrospective. Non-blinded evaluation.
• • The region of interest to measure SUVmax was drawn manually.
• • Limited information was available regarding tumor pathology in some patients. • • TN phenotype had higher SUVmax than luminal A and B. Positive correlation between the percentage of the Ki-67 proliferation index and SUVmax. Highgrade disease had a higher SUVmax than low grade.
• • Small sample. Single-center design.
II
Yoon et al. 55 
• •
Prospective. 43 patients.
• • Inclusion criteria: LABC and IDC.
• • 68Ga-RGD PET/CT and 18F-FDG PET/CT.
• • Objective: correlation of functional imaging parameters (SUVmax and SUVavg) with immunohistochemical parameters and molecular subtypes.
• • Quantitative FDG PET parameters (SUVmax and SUVavg) were significantly higher in the ERnegative and the PR-negative groups.
• • Only the ER/PR−, HER2− subgroup showed a significant positive correlation between FDG and RGD PET parameters (r = 0.59, p = 0.03 for SUVmax).
• • Small sample.
• • Particularly, the ER/PR+ and HER2(+) subgroup tended to have a large standard error; thus, the related results might be affected by a certain degree of bias. • • ALN SUVmax was significantly higher in patients with recurrence than in those who were disease-free (recurrence group: 5.2 ± 2.3 vs disease-free group:
1.9 ± 1.9, p = 0.0001).
• • Only node-positive patients were enrolled.
• • Axillary region of interest was manually drawn.
• • SUV of small metastatic ALN may be underestimated because of partial-volume effect and the limited resolution of PET.
• • Short follow-up (3 years).
III
Groheux et al. 39 
• •
Prospective. 254 patients.
• • Inclusion criteria: clinical stages II-III BC.
• • Objective: impact of PET stage on prognosis.
• • Reference standard: follow-up for 2 years (189 patients evaluated).
• • Survival was significantly shorter in the 47 patients scored M1 on 18FDG-PET-CT than in those scored M0, with a 3-year disease-specific survival of 57% versus 88% (p < 0.001). In multivariable analysis, only distant disease on PET-CT and triple-negative phenotype were significant prognostic factors. The relative risk of death was 26.60 (95% CI: 6.60-102.62) for M1 vs M0 patients.
• • Short follow-up.
II
Joo Hyun et al. 58 
• •
Retrospective. 441 patients.
• • Inclusion criteria: operable BC. CT of patients with BC may not have additional prognostic value compared with conventional staging.
• • SUVmax measurements acquired from two different PET/CT scanners.
• • There was no ALN quantification due to very low SUV in many ALNs.
• • • Reference standard: clinical follow-up (median follow-up of 37 months).
• • PET/CT M0 compared with M1 patients showed significantly better PFS (p = 0.001), but OS was not significantly different between the metastatic and nonmetastatic groups (p = 0.1).
• • No significant differences in OS or PFS were observed between patients with high and moderate tumor FDG uptake using a SUVmax cutoff of 5, or between those with high and moderate tumor enhancement on DCE-CT.
• • • Multivariate analysis using Cox proportional hazard regression model revealed high SUVmax and negative ER status as significant prognostic factors.
• • • High risk: triple-negative or a TLG30% > 158 g or both.
The 5-year PFS rates for stage III disease among patients with low-risk BC was 85% versus 68% among those with high-risk BC. For patients at stage IV, the 5-year PFS rates were 45% for patients with low-risk BC and 9% for patients with high-risk BC. Patients with stage III and high-risk BC had OS rates similar to those for patients with stage IV and low-risk BC (p = 0.552).
• • The TLG30% from pre-treatment PET/CT was independently associated with survival outcomes and appears to be able to effectively stratify patients with both stage III and stage IV BC.
• • • Two-year disease-specific survival was 18% among patients with distant metastases on baseline PET/CT.
In patients without distant metastases, a high SUVmax at baseline was associated with shorter EFS.
• useful prior to surgery or neoadjuvant chemotherapy, based on the high rate of detection of distant metastases, ranging from 6% to 26%. 16, 20, 23, 27 The percentage of patients with extra-ALN involvement detected by PET/CT in locally advanced BC ranges from 10% to 29%. [14] [15] [16] Moreover, in this setting, given the high prevalence of lymph node involvement (up to 80%), 18F-FDG PET/ CT's high negative predictive value in lymph nodes adds to its usefulness. 12, 15 Patients younger than 40 years usually have more aggressive phenotypes of BC, which are more easily detected by 18F-FDG PET/CT. 30, 31 Thus, PET/CT can be useful if younger age is associated with higher risk disease.
Comparison of 18F-FDG PET/CT with other diagnostic techniques
Several studies have found that 18F-FDG PET/CT is more accurate than conventional imaging (e.g. US) in the detection of axillary and extra-axillary (internal mammary) lymph node metastases and bone metastases. [16] [17] [18] 20, 23, 24, 36, 38 However, methodological shortcomings in some of these studies reduce their value in addressing the real diagnostic impact of 18F-FDG PET/CT. The superiority of 18F-FDG PET/CT with respect to conventional imaging for detecting extra-ALNs and metastatic disease acquires more relevance in locally advanced BC. 20, 21, 23 Unfortunately, the three meta-analyses that examined 18F-FDG PET/CT's value in detecting distant metastases were limited by the inclusion of patients regardless of their treatment status. [24] [25] [26] 
Diagnostic and prognostic impact of 18F-FDG PET/CT
18F-FDG PET/CT imaging changes the initial staging by conventional imaging in 5% to 52% of cases; the percentage is lower in patients with early-stage or operable BC 13 and higher in those with locally advanced BC or inflammatory BC. 11, 41, 42, 46 18F-FDG PET detects distant metastases in more than 20% of patients with locally advanced BC 14, 16, 20, 27, 28, 31, 37, 39, 40 and changes the initial staging in up to 52% of patients with inflammatory BC. [29] [30] [31] [32] Other authors have reported changes in N stage based on the diagnosis of unsuspected metastatic extraALNs (N3). These findings are significantly more likely in patients with at least stage IIB BC (considered locally advanced BC by some authors or at least BC in which neoadjuvant chemotherapy is indicated), in whom PET/ CT detected extra-ALN in 5%-29%. 14, 16, 37, 39, 40, 43, 46 Although the evidence seems stronger for stages IIB and III BC, the heterogeneous populations and the predominantly retrospective design used in the studies may explain the differences obtained and the lack of reproducibility of the results.
Another limitation is that most of the studies evaluated did not histologically confirm all the suspicious or pathological lesions detected by 18F-FDG PET/CT; some studies used other imaging techniques to confirm the lesions, although they are less accurate than 18F-18F-FDG PET/CT, especially for bone and morphologically normal structures such as small-size lymph nodes. However, despite our strict reference standard, we recognize that it would be unethical to obtain specimens for histological confirmation from all the lesions detected by PET. Given the greater accuracy of 18F-FDG PET/CT with respect to the most morphological imaging techniques, pathologic findings on PET/CT should be considered suspicious for metastases in the absence of other explanations.
Therapeutic impact consists of changes from curative to palliative treatment, changes to the extent of the radiotherapy field, or additional surgical treatment. 40 18F-FDG PET/CT changes the initial treatment in 1%-8% of patients with early-stage BC, in 7%-13% of those with locally advanced BC, 13, 14, 20, 37, 40, 41, 43 and in up to 52% of those with more aggressive tumors such as inflammatory BC. 31 Nevertheless, the therapeutic impact of 18F-FDG PET/CT in early-stage BC is controversial. Jeong et al. 13 reported that the impact of 18F-FDG PET/CT on the initial staging and treatment in patients with early BC with clinically negative axillary nodes was practically null. By contrast, Bernsdorf et al. 41 found a substantial impact on initial staging and on clinical management in patients with early-stage BC and tumors ≥2 cm. Thus, there is insufficient evidence to establish the therapeutic impact of 18F-FDG PET/CT in early-stage BC. By contrast, 18F-FDG PET/CT has a greater therapeutic impact in locally advanced BC. 14, 20, 31, 37 The retrospective nature and lack of histological confirmation were the main limitations of most of the studies included, reducing their evidence level, despite the large number of patients evaluated in some. However, the evidence seems stronger for stages IIB and III of BC.
Glycolytic activity with 18F-FDG PET/CT, tumor biology, and prognosis
Semiquantitative metabolic parameters obtained with 18F-FDG PET/CT provide information about tumor biology. Maximum standardized uptake value (SUVmax) increases with the biological aggressiveness of the tumors; high-grade, hormone receptor-negative, and triple-negative tumors have higher SUVmax than low-grade and hormone receptor-positive tumors. [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] However, a reproducible SUVmax cutoff that would predict tumor biology has yet to be established. A mean SUVmax close to 10 has been reported in triple-negative BC, although the wide dispersion makes it impossible to define an effective cutoff. [51] [52] [53] Differences in SUVmax values are mainly due to the enormous biological heterogeneity of BC, even among tumors of the same molecular phenotype, although differences in PET acquisition (supine vs. prone position) and in the way the region of interest was selected (automatically vs. manually) may also contribute to variation among studies. 49, 52 Another factor making comparisons among studies difficult is that molecular subtype based on immunohistochemistry might not correspond with the molecular subtype determined by the gene expression profile; furthermore, especially in advanced stages where neoadjuvant treatment is indicated, immunohistochemistry is done on imaging-guided core-needle biopsy specimens, so the results are not as reliable as analyses of the entire tumor. 56 However, despite these limitations, 18F-FDG-PET has demonstrated a good correlation with the molecular phenotypes. 51, 53, 55, 56 18F-FDG-PET can have an impact on the patient's prognosis in two ways: by detecting distant metastases occult to other techniques and by detecting glycolytic activity in the primary tumor and ALN. Various authors have compared prognostic stratification at initial staging by 18F-FDG-PET versus conventional imaging. 31, 43 The detection of occult distant metastases on 18F-FDG PET/ CT is associated with shorter survival independent of the molecular phenotypes. 28, 32, 33, 39 With respect to the semiquantitative information from 18F-FDG PET/CT, the prognostic impact of the SUVmax of the primary tumor is controversial. Whereas some authors found no association between tumor 18F-FDG uptake and prognosis, 32, 58 others reported that patients with high tumor uptake had worse outcomes. 28, 47, 59, 61 Furthermore, a single and reproducible SUVmax has yet to be established; cutoff values range from 3 to 6. 28, 59, 61 The variability among studies is probably due to the different immunohistochemical characteristics of the tumors rather than to differences in methodology. However, it is noteworthy to consider how this semiquantitative metric affects the prognosis of both operable and advanced BC, regardless of the biology of the tumor. 28, 32, 33, 39, 47, [57] [58] [59] [60] [61] The lack of reproducibility of SUV has led to explorations of other metrics, such as total lesion glycolysis, although more studies are necessary to assess their impact. 60 The evidence for the prognostic value of SUVmax in ALN is limited, although higher values have been associated with higher recurrence rates. 28, 57, 58 One important aspect is the applicability of the prognostic information derived from 18F-FDG PET. Whereas 18F-FDG PETs increasing the stage initially diagnosed with conventional imaging may modify the planned treatment, the use of information about tumor glycolysis is more controversial, although patients with tumors with high SUVmax should perhaps undergo stricter follow-up than those with tumors with low SUVmax. Thus, despite the high heterogeneity among the studies with respect to clinical stages, tumor biology (inflammatory BC, triple-negative BC), end-points (overall survival (OS), progression-free survival (PFS), disease-free survival (DFS)), methodology (breast, ALN), and design (retrospective or prospective), all the studies found that PET/CT has prognostic value in BC. 28, 32, 33, 39, 47, [57] [58] [59] [60] [61] 
Cost-effectiveness of 18F-FDG PET/CT
The evidence on the cost-effectiveness of 18F-FDG-PET or PET/CT in BC is limited. Meng et al. 63 concluded that MRI was the most cost-effective strategy to replace sentinel lymph node biopsy, but also pointed out that further studies using up-to-date techniques in larger samples are required to obtain more accurate data on the sensitivity and specificity of MRI. Sloka et al. 62 used PET/CT to calculate the cost savings for lymph node staging in early BC against ALN dissection, a context with reduced applicability. In summary, more studies are needed to evaluate cost-effectiveness of 18F-FDG-PET in patients with BC.
Conclusion
18F-FDG PET/CT is not recommended in early BC, although evidence supports its use in locally advanced BC based on improved regional and distant staging. The evidence for systematically recommending 18F-FDG PET/ CT in triple-negative BC is more limited, and further studies are necessary to assess the real diagnostic and therapeutic impact. There is insufficient evidence to address the cost-effectiveness of 18F-FDG PET/CT. Baseline tumor glycolytic activity is associated with biology and prognosis. Well-designed prospective studies are necessary to determine the real impact of 18F-FDG PET/CT in the more controversial settings of BC staging.
